30.8 C
New York
Saturday, June 6, 2026

Tag: patients

newssourceFORcompanyinformationcontent1marketreleases

Premier Health of America Announces Grant of Management Cease Trade Order

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health”, or the “Company”) announces that, further to its press release dated June 2, 2026, the Autorité des marchés financiers, as the Company’s principal regulator, has granted a management cease trade order (the “MCTO”) under National Policy 12-203 – Management Cease Trade Orders.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C.,...

St. Joseph’s Children’s Hospital Cancer Survivor Advocates for Children’s Health Care on Capitol Hill

TAMPA, Fla., June 5, 2026 /PRNewswire/ -- This week, 7-year-old Mikey Hartnett and his parents joined leaders from BayCare and St. Joseph's Children's Hospital...

Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

New clinical findings further reinforce therapeutic potential of vapendavir as targeted approach to preventing rhinovirus-driven COPD exacerbationsWASHINGTON, June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Gift of Life Marrow Registry Gala Celebrates First-Time Meetings Between Two Transplant Recipients and Their Lifesaving Donors

Gift of Life Marrow Registry hosted its annual NYC Gala, where two transplant recipients, including a 13-year-old boy, were united with their donors.

Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients...

PRESS RELEASE 

Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Pines of Sarasota Healthcare, LLC Provides Notice Following Data Security Incident

SARASOTA, Fla., June 5, 2026 /PRNewswire/ -- Pines of Sarasota Healthcare, LLC experienced a data security incident that involved personal and / or protected...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

ixlayer Launched Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide

Patients Can Now Connect with Licensed Clinicians through the Informed Pain Care Platform to Receive Timely Evaluation and Access to Non-Opioid Treatment Options for...

Trulieve Announces Uplist to NYSE

Subordinate Voting Shares expected to begin trading under ticker "TRLV" on Wednesday, June 10TALLAHASSEE, Fla., June 5, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL)...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers